Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Ruconest "ready for registration" in Rusland

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,905 24 apr 2024 17:35
  • -0,004 (-0,39%) Dagrange 0,893 - 0,917
  • 6.519.524 Gem. (3M) 6,9M

Ruconest "ready for registration" in Rusland

3 Posts
| Omlaag ↓
  1. [verwijderd] 29 januari 2015 13:31


    "For a couple of years HAE has been one of 24 rare diseases
    officially included on the list with obligations by the government
    to treat patients. Presently Firazyr and Danazol is available in
    Russia - and Ruconest is ready for registration, while Berinert is
    registered but not available on the market yet. It is not easy to
    determine the exact number of Russian care centers and hospitals
    that are capable in HAE diagnostic and treatment. It is often
    particular physicians that take care of HAE patients in regions."

    www.haei.org/sites/default/files/publ...
    ====================================================================

    Hier ligt dan hopelijk binnenkort een mooie taak voor SOBI want volgens de nieuwe distributie-overeenkomst:

    "Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine"
  2. [verwijderd] 29 januari 2015 13:47
    Ook uit de nieuwsbrief van de HAE-Organization een beschrijving van de hordes die de HAE-patiënt in Brazilië moet nemen om aan de nieuwste, goede medicatie te komen. Zelfs een proces tegen de staat hoort daar bij. Wat mogen we blij zijn in Nederland te leven als je dit leest.

    "Brazilian patients have had access to Firazyr since 2011 and Berinert since August 2014 – and both of them will be available for self administration later on in 2015.
    While the price of tranexamic acid is 8 USD for a pack of 12 (250 mg), Danazol costs 58 USD for a pack of 50 (100 mg). With tranexamic acid the patient pays for the medicine or gets it for free in (a few) public hospitals. As for Danazol it is registered for HAE treatment and is distributed for free in hospitals provided the patient has a prescription. Oxandrolone is formulated and a few drugstores make it.
    Both Firazyr and Berinert are allowed in Brazil as these medicines are registered with Anvisa, the Brazilian Health Surveillance Agency. However, they don’t have clinical protocol for HAE in Brazil yet - and that leads to a pretty special situation: To get the medication the patient must ask his or her doctor to make an individual medical report about the patient and HAE requesting
    for Firazyr or Berinert. The patient then has to send the medical report and personal documents to a lawyer and provided that the patient pays for the legal assistance the lawyer will make a lawsuit against the state. Only after this bureaucratic and laborious process the patient will receive the medicine.
    To make things just a little easier for the HAE patients in Brazil, ABRANGHE has joined forces with an advocacy organization that makes this process free for the patients registered with the Brazilian HAE organization.
    Usually there will be some insurance coverage when a patient has an acute attack in a hospital. However, it can be hard to get the proper medicine at that moment. Presently there is only clinical protocol for Danazol, so most acute attacks are treated with painkillers or fresh plasma. For prophylactic treatment the doctors use Danazol, tranexamic acid or Oxondrolone. Some physicians are trying to change to Firazyr and Berinert but they only prescribe these kinds of medicine if the patient is able to pay on his or her own or by filing a lawsuit.
    Up until now the patients filing lawsuits against the state have won these lawsuits. Once won, the patient receives a certain amount of medicine, depending on the doctor’s prescription and the specific needs of the patient. Whenever the medicine is used the patient will have to turn to the lawyer again.
    Particularly the first time it is hard because the patients need to attach a lot of documents and a lengthy medical report. In order to help the members ABRANGHE has developed a model that makes the process easier for patients as well as doctors who haven’t dealt with HAE before.
    Presently some Brazilian physicians are trying to get Firazyr and Berinert added to the Anvisa’s drug list. When that happens there will no longer be any need for individual lawsuits.
  3. [verwijderd] 29 januari 2015 16:59

    www.haei.org/sites/default/files/publ...
    ====================================================================

    Hier ligt dan hopelijk binnenkort een mooie taak voor SOBI want volgens de nieuwe distributie-overeenkomst:

    "Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine"

    goed nieuws!bedankt voor je inbreng. nu is pharming aan zet
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  2. 18 apr Pharming rondt plaatsing obligaties af 5
  3. 18 apr Pharming vervangt converteerbare lening 6
  4. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  5. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  6. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  7. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2
  8. 13 mrt Slotcall: Twijfel slaat toe bij chippers, AEX sluit iets lager na wispelturige sessie
  9. 11 mrt Beursblik: hogere jaaromzet Pharming verwacht
  10. 11 mrt AEX gaat opnieuw rode opening tegemoet, Japan ontloopt recessie maar Nikkei duikelt 1

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!